Financial Performance: 111, Inc. reported net revenues of RMB 3.0 billion (approximately $421.5 million) for Q3 2025, reflecting a 16.7% year-over-year decline, yet achieved non-GAAP operational profitability for the third consecutive quarter amidst macroeconomic challenges.
Strategic Shift: The company divested 100% equity interests in three self-operated subsidiaries, which may temporarily impact revenue but strengthens liquidity and profitability by transitioning to an asset-light model, enhancing long-term financial health.
Supply Chain Optimization: Through the ongoing 'MANTIANXING' initiative, the fulfillment center network has expanded, generating RMB 498 million in inventory value, driving 20.5% GMV growth and 31.0% increase in customer count, significantly enhancing overall competitiveness.
Future Outlook: 111, Inc. aims to build an AI-powered pharmaceutical procurement transaction platform, leveraging AI to optimize decision-making and enhance customer experience, which is expected to unlock long-term value for shareholders.
YI
$3.4198+Infinity%1D
Analyst Views on YI
About YI
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
